Xencor
Yahoo Finance • 5 months ago
Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example, after five long years the Xencor, Inc. (NASDAQ:XNCR) share price is a whole 52% lower. That is extremely sub-op... Full story
Yahoo Finance • last year
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
PASADENA, Calif., November 21, 2023--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases,... Full story
Yahoo Finance • 2 years ago
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
PASADENA, Calif., April 26, 2023--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced t... Full story
Yahoo Finance • 2 years ago
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
PASADENA, Calif., April 17, 2023--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented n... Full story
Yahoo Finance • 2 years ago
Xencor Full Year 2022 Earnings: EPS Beats Expectations
Xencor (NASDAQ:XNCR) Full Year 2022 Results Key Financial Results Revenue: US$164.6m (down 40% from FY 2021). Net loss: US$55.2m (down by 167% from US$82.6m profit in FY 2021). US$0.93 loss per share (down from US$1.42 profit in FY 2021)... Full story
Yahoo Finance • 2 years ago
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platfo... Full story
Yahoo Finance • 2 years ago
Xencor Reports Second Quarter 2022 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif., August 03, 2022--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for t... Full story
Yahoo Finance • 2 years ago
Shares of Xencor Could Be Bought on a 50% Correction
Xencor , with its protein engineering platform, is "developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and autoimmune disorders". In this daily bar chart of XNCR, below, we can see that prices q... Full story
Yahoo Finance • 3 years ago
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
MONROVIA, Calif., April 28, 2022--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced... Full story
